Bronchial hyperresponsiveness decreases through childhood

Limited knowledge exists about development of bronchial hyperresponsiveness (BHR) through adolescence. We aimed to assess changes in and risk factors for BHR in adolescence. From a Norwegian birth cohort 517 subjects underwent clinical examinations, structured interviews and methacholine challenges at age 10 and 16. BHR was divided into four categories: no BHR (cumulative methacholine dose required to reduce FEV1 by 20% (PD20) >16 mu mol), borderline BHR (PD20 <= 16 and >8 mu mol), mild to moderate BHR (PD20 <= 8 and >1 mu mol), and severe BHR (PD20 <= 1 mu mol). Logistic regression analysis was used to assess risk factors and possible confounders. The number of children with PD20 <= 8 decreased from 172 (33%) to 79(15%) from age 10-16 (p < 0.001). Most children (n = 295, 57%) remained in the same BHR (category) from age 10-16 (50% with no BHR), whereas the majority 182 (82%) of the 222 children who changed BHR category, had decreased severity at age 16. PD20 <= 8 at age 10 was the major risk factor for PD20 <= 8 6 years later (odds ratio 6.3), without significant confounding effect (>25% change) of gender, active rhinitis, active asthma, height, FEV1/FVC, or allergic sensitization. BHR decreased overall in severity through adolescence, was stable for the majority of children and only a minority (8%) had increased BHR from age 10 to 16. Mild to moderate and severe BHR at age 10 were major risk factors for PD20 <= 8 at 16 years and not modified by asthma or body size. (C) 2011 Elsevier Ltd. All rights reserved.